
Adding pembrolizumab to dabrafenib and trametinib significantly improves survival in anaplastic thyroid cancer.


coremsg

With the neoadjuvant regimen of pembrolizumab added to dabrafenib and trametinib, survival in BRAF-mutated forms of the highly aggressive cancer can go from months to more than 5 years.

Triple Therapy Boosts Anaplastic Thyroid Cancer Survival

triple-therapy-with-pembrolizumab-improves-anaplastic-thyroid-cancer-survival


Triple Therapy with Pembrolizumab Improves Anaplastic Thyroid Cancer Survival
